4//SEC Filing
SAHA SAURABH 4
Accession 0001847903-25-000119
CIK 0001847903other
Filed
Jul 20, 8:00 PM ET
Accepted
Jul 21, 7:39 PM ET
Size
10.2 KB
Accession
0001847903-25-000119
Insider Transaction Report
Form 4
SAHA SAURABH
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Ordinary Shares
2025-07-21$3.85/sh+55,000$211,750→ 276,017 total - Sale
Ordinary Shares
2025-07-21$15.92/sh−55,000$875,600→ 221,017 total - Exercise/Conversion
Share Option (right to buy)
2025-07-21−55,000→ 150,000 totalExercise: $3.85Exp: 2033-02-01→ Ordinary Shares (55,000 underlying)
Holdings
- 38,000(indirect: By Trust)
Ordinary Shares
Footnotes (5)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.80 to $16.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]These shares are held directly in a trust, for which the Reporting Person and his spouse serve as trustees.
- [F5]1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2023.
Documents
Issuer
Centessa Pharmaceuticals plc
CIK 0001847903
Entity typeother
Related Parties
1- filerCIK 0001861926
Filing Metadata
- Form type
- 4
- Filed
- Jul 20, 8:00 PM ET
- Accepted
- Jul 21, 7:39 PM ET
- Size
- 10.2 KB